Sun Pharmaceuticals has hit out at the proposed draft new pharma pricing policy (NPPP), 2011, which can lead to shortage of drugs and severely hurt the interests of domestic industry and patients.
The draft policy only looks in terms of price reduction, which is a short-term approach and neither addresses the needs of the industry nor those of patients. The draft NPPP, 2011 intends to bring 60% of the total domestic pharmaceutical market amounting to nearly Rs 29,000 crore under price control by bringing all the 348 drugs specified in the National List of Essential Medicines 2011 under price control.
Sun Pharmaceutical Industries manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: